High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition
- 17 October 2006
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 103 (42), 15588-15593
- https://doi.org/10.1073/pnas.0604524103
Abstract
Background Those affected by advanced fibrotic interstitial lung diseases (ILDs) have considerable unmet symptom and psychological needs. Case conferencing has been proposed to address these issues, but requires evaluation. Aim To obtain preliminary information on the impact of a case conference intervention delivered in the home (Hospital2Home) on palliative care concerns of patients and their carers, and to evaluate feasibility and acceptability. Methods Hospital2Home was trialled at a specialist centre using a Phase II fast-track randomised controlled trial with qualitative interviews. The primary outcome for effect was mean change from baseline of Palliative Care Outcome Scale (POS) (a measure of symptoms and concerns) at 4 weeks. Secondary outcomes included symptom control, quality of life, consent and recruitment rates and percentage of patients in the fast-track group receiving case conferences within 14 days. Results 53 patients were recruited (26 fast-track, 27 controls). Mean (SD) POS scores at 4 weeks were −5.7 (7.5) fast-track vs −0.4 (8.0) control, (mean change difference between the two arms was −5.3 (95% CI −9.8 to −0.7) independent t test p=0.02); effect size (95% CI) −0.7 (−1.2 to −0.1). The secondary outcomes of quality of life, anxiety and depression were superior in the fast-track arm, and none were worse. Qualitative findings corroborate these data. Recruitment was successful and 53/67 (79%) of eligible patients consented. 6/25 (24%) had case conferences within 14 days. Conclusions Community case conferences improve palliative symptoms and quality of life after 4 weeks. Hospital2Home for the most part is both feasible and acceptable. It now requires further testing in multicentre trials. Trial registration number NCT01450644Keywords
This publication has 52 references indexed in Scilit:
- Mammalian Staufen1 Recruits Upf1 to Specific mRNA 3′UTRs so as to Elicit mRNA DecayCell, 2005
- Hypermutation of HIV-1 DNA in the Absence of the Vif ProteinScience, 2003
- Protein composition of human prespliceosomes isolated by a tobramycin affinity-selection methodProceedings of the National Academy of Sciences, 2002
- Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif proteinNature, 2002
- Nucleolin Associates with a Subset of the Human Ro Ribonucleoprotein ComplexesJournal of Molecular Biology, 2002
- Alu repeats and human genomic diversityNature Reviews Genetics, 2002
- An Anthropoid-Specific Locus of Orphan C to U RNA-Editing Enzymes on Chromosome 22Genomics, 2002
- The Heterogeneous Nuclear Ribonucleoproteins I and K Interact with a Subset of the Ro Ribonucleoprotein-associated Y RNAs in Vitro and in VivoJournal of Biological Chemistry, 2001
- Analysis of the molecular composition of Ro ribonucleoprotein complexesEuropean Journal of Biochemistry, 2000
- Alu elements and the human genome.Genetica, 2000